Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models

被引:10
|
作者
Yang, Mei [1 ]
Guan, Tian [2 ]
Chen, Chun-Fa [3 ]
He, Li-Fang [3 ]
Wu, Hao-Ming [3 ]
Zhang, Ren-Dong [3 ]
Li, Yun [2 ]
Lin, Yan-Chun [2 ]
Zeng, Haoyu [2 ,6 ]
Wu, Jun-Dong [3 ,4 ,5 ]
机构
[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Canc Ctr, Dept Breast Canc, Shantou, Guangdong, Peoples R China
[2] Guangdong Procapzoom Biosci Inc, Guangzhou, Guangdong, Peoples R China
[3] Shantou Univ, Canc Hosp, Med Coll, Breast Ctr, Shantou, Guangdong, Peoples R China
[4] Guangdong Prov Key Lab Breast Canc Diag & Treatmen, Shantou, Guangdong, Peoples R China
[5] Guangdong Prov Key Lab Breast Canc Diag & Treatmen, Shantou 515041, Guangdong, Peoples R China
[6] Guangdong Procapzoom Biosci, Dept Stem Cell Res, 11 Guangpuzhong Rd, Guangzhou 510700, Guangdong, Peoples R China
关键词
CAR-NK; iPSCs; TNBC; pre-clinical; MSLN;
D O I
10.1097/CJI.0000000000000483
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The emergence of immunotherapy has introduced a promising, novel approach to cancer treatment. While multiple chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable clinical efficacy against leukemia, their effect on solid tumors has been limited. One potential option for treating solid tumors is the engineering of natural killer (NK) cells with CARs. Mesothelin (MSLN), a tumor differentiation antigen, is expressed on triple-negative breast cancer (TNBC) cells, making it a potential target for CAR-NK therapy in the treatment of TNBC. We first constructed induced pluripotent stem cells with stable anti-MSLN-CAR expression and subsequently differentiated these cells into mesothelin-targeted CAR-NK (MSLN-NK) cells. We then assessed the effects of MSLN-NK cells on TNBC cells both in vitro (using the MDA-MB-231 cell line), in vivo (in a CDX mouse model), and ex vivo (using patient-specific primary cells and patient-specific organoids), in which MSLN surface expression was confirmed. Our CDX study results indicated that MSLN-NK cells effectively killed MDA-MB-231 (MD231) cells in vitro, reduced tumor growth in the CDX mouse model of TNBC, and lysed patient-specific primary cells and patient-specific organoids derived from the tumor samples of TNBC patients. Our data demonstrated that MSLN-NK cells had high efficacy on killing TNBC cells in in vitro, in vivo, and ex vivo. Therefore, MSLN-NK could be a promising treatment option for TNBC patients.
引用
收藏
页码:285 / 294
页数:10
相关论文
共 50 条
  • [31] Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer
    Ramani, Vishnu C.
    Lemaire, Clementine A.
    Triboulet, Melanie
    Casey, Kerriann M.
    Heirich, Kyra
    Renier, Corinne
    Vilches-Moure, Jose G.
    Gupta, Rakhi
    Razmara, Aryana M.
    Zhang, Haiyu
    Sledge, George W.
    Sollier, Elodie
    Jeffrey, Stefanie S.
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [32] Identification of Triple-Negative Primary Breast Cancer Xenograft Models with High Numbers of Circulating and Disseminated Tumor Cells.
    Giuliano, M.
    Christiny, P. I.
    Zhang, X.
    Mao, S.
    Contreras, A.
    Lewis, M. T.
    Rimawi, M. F.
    Osborne, C. K.
    Schiff, R.
    Trivedi, M. V.
    CANCER RESEARCH, 2011, 71
  • [33] Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer
    Vishnu C. Ramani
    Clementine A. Lemaire
    Melanie Triboulet
    Kerriann M. Casey
    Kyra Heirich
    Corinne Renier
    José G. Vilches-Moure
    Rakhi Gupta
    Aryana M. Razmara
    Haiyu Zhang
    George W. Sledge
    Elodie Sollier
    Stefanie S. Jeffrey
    Breast Cancer Research, 21
  • [34] RON-Targeted Antibody-Drug Conjugate Therapy Ablates Cancer Stem Cells and Induces Longterm Tumor Regressions in Preclinical Models of Triple Negative Breast Cancer
    Suthe, S.
    Yao, H.
    Wang, M.
    AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (10): : 2411 - 2412
  • [35] Curcumin: a calixarene derivative micelle potentiates anti-breast cancer stem cells effects in xenografted, triple-negative breast cancer mouse models
    Chen, Wei
    Li, Lin
    Zhang, Xiaofen
    Liang, Yuan
    Pu, Zhijun
    Wang, Lingfeng
    Mo, Jingxin
    DRUG DELIVERY, 2017, 24 (01) : 1470 - 1481
  • [36] Exosomal GPT2 derived from triple-negative breast cancer cells promotes metastasis by activating BTRC
    Cui, Mingqing
    Peng, Jiawei
    Zhou, Yuanyuan
    Wang, Xixi
    Cui, Daxiang
    THORACIC CANCER, 2023, 14 (21) : 2018 - 2025
  • [37] Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer
    Park, In Hae
    Yang, Han Na
    Lee, Kyoung Joo
    Kim, Tae-Sik
    Lee, Eun Sook
    Jung, So-Youn
    Kwon, Youngmee
    Kong, Sun-Young
    ONCOTARGET, 2017, 8 (20) : 32722 - 32730
  • [38] Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line
    Moreira, Milene Pereira
    Franco, Eliza Pereira
    Barros, Barbara Avelar Ferreira
    dos Anjos, Bianca Rocha
    Almada, Daniela de Gouvea
    Barbosa, Isabela Nery Tavares
    Braga, Leticia da Conceicao
    Cassali, Geovanni Dantas
    Maria Silva, Luciana
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 734
  • [39] Fn14-Directed DART Nanoparticles Selectively Target Neoplastic Cells in Preclinical Models of Triple-Negative Breast Cancer Brain Metastasis
    Carney, Christine P.
    Kapur, Anshika
    Anastasiadis, Pavlos
    Ritzel, Rodney M.
    Chen, Chixiang
    Woodworth, Graeme F.
    Winkles, Jeffrey A.
    Kim, Anthony J.
    MOLECULAR PHARMACEUTICS, 2023, 20 (01) : 314 - 330
  • [40] The influence of cytochalasin B-induced membrane vesicles derived from mesenchymal stem cells overexpressing TRAIL on the expression of apoptotic genes in triple-negative MDA-MB-231 breast cancer cells
    Pukhalskaia, T. V.
    Chulpanova, D. S.
    Rizvanov, A. A.
    Solovyeva, V. V.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A143 - A143